Herbert Stangl
Overview
Explore the profile of Herbert Stangl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
926
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weber F, Axmann M, Sezgin E, Amaro M, Sych T, Hochreiner A, et al.
Membranes (Basel)
. 2024 Dec;
14(12.
PMID: 39728711
The viscoelastic properties of biological membranes are crucial in controlling cellular functions and are determined primarily by the lipids' composition and structure. This work studies these properties by varying the...
2.
Fleischhacker V, Milosic F, Bricelj M, Kuhrer K, Wahl-Figlash K, Heimel P, et al.
Aging Cell
. 2024 Apr;
23(6):e14139.
PMID: 38578073
Age-induced decline in osteogenic potential of bone marrow mesenchymal stem cells (BMSCs) potentiates osteoporosis and increases the risk for bone fractures. Despite epidemiology studies reporting concurrent development of vascular and...
3.
Steinbauer S, Konig A, Neuhauser C, Schwarzinger B, Stangl H, Iken M, et al.
Sci Rep
. 2024 Feb;
14(1):3547.
PMID: 38347122
Cholesterol deposition in intimal macrophages leads to foam cell formation and atherosclerosis. Reverse cholesterol transport (RCT), initiated by efflux of excess cholesterol from foam cells, counteracts atherosclerosis. However, targeting RCT...
4.
Sych T, Schlegel J, Barriga H, Ojansivu M, Hanke L, Weber F, et al.
Nat Biotechnol
. 2023 Jun;
42(4):587-590.
PMID: 37308687
We introduce a method, single-particle profiler, that provides single-particle information on the content and biophysical properties of thousands of particles in the size range 5-200 nm. We use our single-particle...
5.
Zierfuss B, Stangl H, Schernthaner G
Atherosclerosis
. 2023 Mar;
370:1-2.
PMID: 36914540
No abstract available.
6.
Metz M, Baumgartner C, Stangl H, Scherer T
STAR Protoc
. 2023 Feb;
4(1):102089.
PMID: 36853686
Tracer techniques to assess very-low-density lipoprotein (VLDL) secretion in humans are expensive, are time consuming, and require mathematical models to estimate VLDL kinetics. Here, we describe an alternative, time- and...
7.
Zierfuss B, Hobaus C, Feldscher A, Hannes A, Mrak D, Koppensteiner R, et al.
Atherosclerosis
. 2022 Oct;
363:94-101.
PMID: 36280470
Background And Aims: Despite low LDL-C goals, the residual risk for further cardiovascular (CV) events in patients with peripheral artery disease (PAD) remains high. Lipoprotein (a) (Lp(a)) is a known...
8.
Metz M, Beghini M, Wolf P, Pfleger L, Hackl M, Bastian M, et al.
Cell Metab
. 2022 Oct;
34(11):1719-1731.e5.
PMID: 36220067
Recombinant human leptin (metreleptin) reduces hepatic lipid content in patients with lipodystrophy and overweight patients with non-alcoholic fatty liver disease and relative hypoleptinemia independent of its anorexic action. In rodents,...
9.
Oberle R, Kuhrer K, Osterreicher T, Weber F, Steinbauer S, Udonta F, et al.
Life Sci Alliance
. 2022 May;
5(9).
PMID: 35577388
Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous...
10.
Zierfuss B, Hobaus C, Herz C, Koppensteiner R, Stangl H, Schernthaner G
Thromb Haemost
. 2022 Apr;
122(10):1804-1813.
PMID: 35436798
Low-density lipoprotein-cholesterol reduction showed a strong reduction of cardiovascular (CV) event rates in CV disease. However, the residual risk of future CV events remains high, which especially extends to peripheral...